Business Wire

1. Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
   9/1/2010
   Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), for advanced development of the company's third generation anthrax vaccine candidate.
2. GreenVax Selects Xcellerex XDR Single-Use Bioreactors For New Vaccine And Biotherapeutics Program
   8/31/2010
   Xcellerex, Inc. announced today that Project GreenVax has agreed to acquire XDR GMP single-use production bioreactors from Xcellerex. The systems will be deployed in a new facility currently under construction in Bryan, Texas.
3. KYTHERA And Bayer Dermatology Unit Intendis Enter Licensing And Development Agreement For Adipolytic Agent ATX-101
   8/30/2010
   KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada.
4. BARDA Funds Drug Development For Biothreats, Antibiotic Resistance
   8/30/2010
   The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to develop an antibiotic that could be used against possibly two types of bioterrorism as well as common infections that are becoming resistant to antibiotics.
5. Lineagen, Inc. Closes $5M To Complete $10.8M Series A Round
   8/30/2010
   Lineagen, Inc., a developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders and others, today announced that PrairieGold Venture Partners has joined Lineagen's existing institutional venture investors in a further $5M closing of its Series A round, which completes Lineagen's $10.8M Series A financing.
6. Nanotherapeutics Submits Investigational New Drug Application To FDA For Clinical Testing Of Oral Drug To Treat Radiation Exposure
   8/30/2010
   Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid).
7. Genzyme Confirms Receipt of Unsolicited Proposal
   8/30/2010
   Genzyme Corp. (NASDAQ: GENZ) today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash.
8. Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration With Merck KGaA For Cancer Treatment
   8/27/2010
   Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany.
9. Alnylam And Collaborators Publish New Pre-Clinical Research On Therapeutic Silencing Of Parkinson’s Disease Gene
   8/23/2010
   Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS).
10. Taligen Closes $10M Series B Financing Tranche
    8/23/2010
    Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.

First 1 2 3 4 5 6 7 8 9 10 10 (Last)